Page last updated: 2024-11-11

bo 653

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2,3-dihydro-5-hydroxy-2,2-dipentyl-4,6-di-tert-butylbenzofuran: an antiatherogenic antioxidant; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9800472
CHEMBL ID104186
SCHEMBL ID5055886
MeSH IDM0277494

Synonyms (17)

Synonym
CHEMBL104186
bo-653
157360-23-1
2,3-dihydro-5-hydroxy-2,2-dipentyl-4,6-di-tert-butylbenzofuran
2vsp9t5lrx ,
unii-2vsp9t5lrx
bo 653
2,3-dihydro-5-hydroxy-4,6-di-tert-butyl-2,2-dipentylbenzofuran
4,6-ditert-butyl-2,2-dipentyl-3h-benzofuran-5-ol
4,6-di-t-butyl-5-hydroxy-2,2-di-n-pentyl-2,3-dihydrobenzofuran
AGURKSYKTJQPNA-UHFFFAOYSA-N
4,6-di-tert-butyl-5-hydroxy-2,2-dipentyl-2,3-dihydrobenzofuran
SCHEMBL5055886
DTXSID20166253
4,6-bis(1,1-dimethylethyl)-2,3-dihydro-2,2-dipentyl-5-benzofuranol
5-benzofuranol, 4,6-bis(1,1-dimethylethyl)-2,3-dihydro-2,2-dipentyl-
4,6-ditert-butyl-2,2-dipentyl-3h-1-benzofuran-5-ol

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"We examined the design of the versatile novel self-emulsifying drug delivery systems (SEDDS) type O/W microemulsion formulation which enhances the oral bioavailability by raising the solubility of poorly water soluble compounds."( The novel formulation design of self-emulsifying drug delivery systems (SEDDS) type O/W microemulsion I: enhancing effects on oral bioavailability of poorly water soluble compounds in rats and beagle dogs.
Araya, H; Hayashi, M; Nagao, S; Tomita, M, 2005
)
0.33
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (12)

Assay IDTitleYearJournalArticle
AID29847Distribution of compound into HDL lipoprotein fraction of WHHL Rabbit's plasma after oral administration2003Journal of medicinal chemistry, Jul-03, Volume: 46, Issue:14
Design and synthesis of 4,6-di-tert-butyl-2,3-dihydro-5-benzofuranols as a novel series of antiatherogenic antioxidants.
AID29926Distribution of compound into VLDL lipoprotein fraction of WHHL Rabbit's plasma after oral administration2003Journal of medicinal chemistry, Jul-03, Volume: 46, Issue:14
Design and synthesis of 4,6-di-tert-butyl-2,3-dihydro-5-benzofuranols as a novel series of antiatherogenic antioxidants.
AID26958cLogP was determined2003Journal of medicinal chemistry, Jul-03, Volume: 46, Issue:14
Design and synthesis of 4,6-di-tert-butyl-2,3-dihydro-5-benzofuranols as a novel series of antiatherogenic antioxidants.
AID28408Distribution of compound into WHHL Rabbit's plasma after oral administration2003Journal of medicinal chemistry, Jul-03, Volume: 46, Issue:14
Design and synthesis of 4,6-di-tert-butyl-2,3-dihydro-5-benzofuranols as a novel series of antiatherogenic antioxidants.
AID100078Inhibition of LDL oxidation induced by cupric ions (CuSO4) at 1 uM expressed as % control.2003Journal of medicinal chemistry, Jul-03, Volume: 46, Issue:14
Design and synthesis of 4,6-di-tert-butyl-2,3-dihydro-5-benzofuranols as a novel series of antiatherogenic antioxidants.
AID100079Inhibition of LDL oxidation induced by cupric ions (CuSO4) at 10 uM expressed as % control.2003Journal of medicinal chemistry, Jul-03, Volume: 46, Issue:14
Design and synthesis of 4,6-di-tert-butyl-2,3-dihydro-5-benzofuranols as a novel series of antiatherogenic antioxidants.
AID100080Inhibition of LDL oxidation induced by soybean lipoxygenase (SLO) at 0.5 uM expressed as % control.2003Journal of medicinal chemistry, Jul-03, Volume: 46, Issue:14
Design and synthesis of 4,6-di-tert-butyl-2,3-dihydro-5-benzofuranols as a novel series of antiatherogenic antioxidants.
AID27547Distribution of compound into LDL lipoprotein fraction of WHHL Rabbit's plasma after oral administration2003Journal of medicinal chemistry, Jul-03, Volume: 46, Issue:14
Design and synthesis of 4,6-di-tert-butyl-2,3-dihydro-5-benzofuranols as a novel series of antiatherogenic antioxidants.
AID100081Inhibition of LDL oxidation induced by soybean lipoxygenase (SLO) at 5 uM expressed as % control.2003Journal of medicinal chemistry, Jul-03, Volume: 46, Issue:14
Design and synthesis of 4,6-di-tert-butyl-2,3-dihydro-5-benzofuranols as a novel series of antiatherogenic antioxidants.
AID326215Antioxidant activity assessed as oxygen radical scavenging activity in presence of human plasma by ORAC method relative to control2008Bioorganic & medicinal chemistry letters, Apr-01, Volume: 18, Issue:7
Antioxidant capacity of BO-653, 2,3-dihydro-5-hydroxy-4,6-di-tert-butyl-2,2-dipentylbenzofuran, and uric acid as evaluated by ORAC method and inhibition of lipid peroxidation.
AID226841Inhibition of MCLA chemiluminescence generated by autoxidation of linoleic acid2003Journal of medicinal chemistry, Jul-03, Volume: 46, Issue:14
Design and synthesis of 4,6-di-tert-butyl-2,3-dihydro-5-benzofuranols as a novel series of antiatherogenic antioxidants.
AID326216Antioxidant activity in human plasma assessed as inhibition of cholesteryl ester hydroperoxide formation after 60 mins relative to control2008Bioorganic & medicinal chemistry letters, Apr-01, Volume: 18, Issue:7
Antioxidant capacity of BO-653, 2,3-dihydro-5-hydroxy-4,6-di-tert-butyl-2,2-dipentylbenzofuran, and uric acid as evaluated by ORAC method and inhibition of lipid peroxidation.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (23)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's5 (21.74)18.2507
2000's16 (69.57)29.6817
2010's2 (8.70)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 16.39

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index16.39 (24.57)
Research Supply Index3.26 (2.92)
Research Growth Index4.46 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (16.39)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (4.17%)5.53%
Reviews4 (16.67%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other19 (79.17%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]